Vancomycin Hydrochloride

The success of a recent clinical trial of a wearable patch that tracks a patient's medication levels may indicate that the age of digital blood testing is near. An international research team, which involves researchers from the University of New South Wales, developed and tested a lab-in-a-patch device for continuous molecular monitoring with Australian diagnostics solution developer Nutromics. In a pilot trial – the findings of which have been published in Nature Biotechnology – the patch was used to monitor levels of vancomycin, a last-resort antibiotic that was said to have always been tricky to dose. The patch, which is reportedly more comfortable than standard blood draws, uses synthetic DNA-based sensors, called aptamers, to measure dosage levels. WHY IT MATTERS Following its success, Scientia Professor Justin Gooding from UNSW School of Chemistry points to the possibility of monitoring patients at any time to ensure they receive the best, safest, and most effective treatment. When asked if this breakthrough brings us closer to what could be considered digital blood testing, Prof Gooding told Mobihealth News : "This technology is very close to that vision." "The main scientific hurdles to making the devices have been overcome, and the main engineering hurdles have been solved. The main challenges are [now] around clinical validation, so we feel we are very close." According to Prof Gooding, there are no limits to what a DNA-based sensor patch can detect. "Aptamers have been developed for molecules as small as lactate and as large as large proteins." The main constraint, however, is whether synthetic DNA can bind to the biomarker of interest in the right concentration range. The patch, he emphasised, is ideal for tracking biomarker or drug level change in minutes or hours. Aptamer-based monitoring initially showed potential as a diagnostic tool when it was first applied in laboratory animals. According to Prof Gooding, it took a team of medical practitioners, engineers, and scientists to resolve the previous challenges around sterility and safety of the sensor-based patch. What remains for now, said Prof Gooding, is testing the lab-in-a-patch in large-scale clinical trials to get "an understanding of the relationships between interstitial fluid levels of the biomarker or drug of interest and blood levels." "The other hurdles are then more related to the business, distinct from the technological side of the devices." Trials in ICUs across Australia are underway while Nutromics is working to get regulatory approval in the United States by next year, UNSW mentioned in a media release. Nutromics is also exploring potential applications of the wearable patch, including continuous monitoring in cardiology and supporting triage in emergency departments.

STATEN ISLAND, N.Y., Feb. 16, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will discuss its full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 am ET before the U.S. financial markets open. David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows: Date: Friday, March 13, 2026 Time: 8:00 a.m. ET Toll free (U.S.): 877-790-1503 Access ID: 13758852 Click here for participant International Toll-Free access numbers About Ibezapolstat Ibezapolstat is the Company's lead antibiotic candidate preparing for international Phase 3 clinical trials to treat patients with C. difficile Infection (CDI). Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. As previously announced, the Company has received final EMA and FDA advice for our ibezapolstat pivotal Phase 3 trials. Their advice included and confirmed the non-inferiority study design elements, the patient population, primary and secondary endpoints, and size of the registration safety database. Acurx also now has a clear international roadmap for conduct of its Phase 3 program and, if successful, requirements for US NDA submission and EU Marketing Authorization. Acurx previously announced that it had received positive regulatory guidance from EMA during its Scientific Advice Procedure which confirmed that the clinical, non-clinical and CMC (Chemistry Manufacturing and Controls) information package submitted to EMA supports advancement of the ibezapolstat Phase 3 program and if the Phase 3 program is successful, supports the submission of a Marketing Authorization Application (MAA) for regulatory approval in Europe. The information package submitted to EMA by the Company to which agreement has been reached with EMA included details on Acurx's two planned international Phase 3 clinical trials, 1:1 randomized (designed as non-inferiority vs vancomycin), primary and secondary endpoints, sample size, statistical analysis plan and the overall registration safety database. With mutually consistent feedback from both EMA and FDA, Acurx is well positioned to commence our international Phase 3 registration program In June 2018, ibezapolstat was designated by the U.S. Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted "Fast Track" designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram+ specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). To learn more about Acurx Pharmaceuticals and its product pipeline, please visit . Forward-Looking Statements Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2024, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law. Investor Contact: Acurx Pharmaceuticals, Inc. David P. Luci, President & CEO Tel: 917-533-1469 Email: [email protected] SOURCE Acurx Pharmaceuticals, Inc. 21% more press release views with Request a Demo